2013 Europe; New Product Innovation - Extremolyte Therapeutics for Allergies

Regular Price: USD 1,500.00

Special Price USD 1,275.00

15% OFF

* Required Fields

Regular Price: USD 1,500.00

Special Price USD 1,275.00

PAY BY INVOICE

Be the first to review this product

This research service focuses on insulin and non-insulin therapeutics for the treatment of type 1 and 2 diabetes in Latin America. The insulin and non-insulin markets will experience major changes within the next three years, due to the discovery of new drugs. Focus is currently placed on the development of molecules that can help with patients adherence to treatment by offering one weekly drug dose for managing the chronic disease. This deliverable includes information regarding market background, dynamics, challenges, trends, and access. The base year is 2013. Also, provided are a detailed analysis of products on the market and in development within Latin America, as well as clinical trial details and projected drugs launch timelines.

Table of Contents

2013 Europe; New Product Innovation - Extremolyte Therapeutics for Allergies2013 Europe; New Product Innovation - Extremolyte Therapeutics for Allergies2013 Europe; New Product Innovation - Extremolyte Therapeutics for Allergies




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 22-May-18

Region : Latin America

Release Date : 19-Apr-18

Region : Latin America

Release Date : 12-Apr-18

Region : Latin America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.